Evidence map›Paper›PMID 36057265›Full record

ReviewThe lancet. Gastroenterology & hepatology2022

The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms.

Tommaso Pollini, Volcan Adsay, Gabriele Capurso, Marco Dal Molin, Irene Esposito, Ralph Hruban, Claudio Luchini, Laura Maggino, Hanno Matthaei, Giovanni Marchegiani and 6 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The lancet. Gastroenterology & hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Tommaso PolliniDivision of Surgical Oncology, Department of Surgery, University of California San Francisco, San Francisco, CA, USA; Department of General and Pancreatic Surgery, The Pancreas Institute, Section of Pathology University of Verona, Verona, Italy.
Volcan AdsayDepartment of Pathology, Koç University Hospital and Koç University Research Center for Translational Medicine, Istanbul, Turkey.
Gabriele CapursoDepartment of Pancreatobiliary Endoscopy and Endosonography, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele, Milan, Italy.
Marco Dal MolinDepartment of Surgery, University of Maryland Medical Center, Baltimore, MD, USA.
Irene EspositoDepartment of Pathology, Heinrich Heine University and University Hospital of Düsseldorf, Düsseldorf, Germany.
Ralph HrubanDepartment of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MA, USA.
Claudio LuchiniDepartment of Diagnostics and Public Health, Section of Pathology University of Verona, Verona, Italy.
Laura MagginoDepartment of General and Pancreatic Surgery, The Pancreas Institute, Section of Pathology University of Verona, Verona, Italy.
Hanno MatthaeiDepartment of Surgery, University Hospital of Bonn, Bonn, Germany.
Giovanni MarchegianiDepartment of General and Pancreatic Surgery, The Pancreas Institute, Section of Pathology University of Verona, Verona, Italy.
Aldo ScarpaDepartment of Diagnostics and Public Health, Section of Pathology University of Verona, Verona, Italy.
Laura D WoodDepartment of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MA, USA.
Claudio BassiDepartment of General and Pancreatic Surgery, The Pancreas Institute, Section of Pathology University of Verona, Verona, Italy.
Roberto SalviaDepartment of General and Pancreatic Surgery, The Pancreas Institute, Section of Pathology University of Verona, Verona, Italy.
Mari Mino-KenudsonDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Ajay V MakerDivision of Surgical Oncology, Department of Surgery, University of California San Francisco, San Francisco, CA, USA. Electronic address: ajay.maker@ucsf.edu.
Massachusetts General Hospital · USUniversity Hospital Bonn · DEUniversity of Maryland, Baltimore · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Stimulating Lymphocyte Activation Combined with Inhibition of Immunosuppressive Signals in Colon Cancer MetastasesR37CA238435 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Ajay V. Maker · 2020 to 2026
$2.5M
NCI NIH HHS P30 CA006973NCI NIH HHS R37 CA238435
6 · The paper itself

Abstract

Pancreatic intraductal papillary mucinous neoplasms (IPMNs) have gained substantial attention because they represent one of the only radiographically identifiable precursors of invasive pancreatic ductal adenocarcinoma. Although most of these neoplasms have low-grade dysplasia and will remain indolent, a subset of IPMNs will progress to invasive cancer. The role of the immune system in the progression of IPMNs is unclear, but understanding its role could reveal the mechanism of neoplastic progression and targets for immunotherapy to inhibit progression or treat invasive disease. The available evidence supports a shift in the immune composition of IPMNs during neoplastic progression. Although low-grade lesions contain a high proportion of effector T cells, high-grade IPMNs, and IPMNs with an associated invasive carcinoma lose the T-cell infiltrate and are characterised by a predominance of immunosuppressive elements. Several possible therapeutic strategies emerge from this analysis that are unique to IPMNs and its microbiome.

Indexed as

Adenocarcinoma, MucinousCarcinoma, Pancreatic DuctalMicrobiotaPancreatic NeoplasmsHumansPancreatic DuctsTumor Microenvironment

Identifiers

PMID36057265
PMCPMC9844533
OpenAlexW4297573681

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.